“Some of the design changes include centralised review of investigator ratings and universal use of advanced Canfield imaging technology to support clinical assessments and patient tracking."
This says a lot in my opinion. They may not be able to 100% prove it, or don’t want to upset future customers, but for me this suggests some genuine concern about the subjective assessment of skin improvement during the acne trials in the USA.
“Some of the design changes include centralised review of...
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $615.4M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.8¢ | $1.949M | 5.840M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2985 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 420471 | 4 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |